{"organizations": [], "uuid": "2ea554c49efef364a0830c0dec0cb7313e0cf231", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s4.reutersmedia.net/resources/r/?m=02&d=20180126&t=2&i=1225411215&w=1200&r=LYNXMPEE0P0DZ", "site_section": "http://feeds.reuters.com/reuters/UKhealth/", "section_title": "Reuters: Health News", "url": "https://uk.reuters.com/article/us-astrazeneca-copd/astrazenecas-inhaler-for-lung-disease-shows-improved-function-in-late-stage-trail-idUKKBN1FF0SF", "country": "US", "domain_rank": 408, "title": "AstraZeneca's inhaler for lung disease shows improved function in late stage trail", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-26T10:06:00.000+02:00", "replies_count": 0, "uuid": "2ea554c49efef364a0830c0dec0cb7313e0cf231"}, "author": "", "url": "https://uk.reuters.com/article/us-astrazeneca-copd/astrazenecas-inhaler-for-lung-disease-shows-improved-function-in-late-stage-trail-idUKKBN1FF0SF", "ord_in_thread": 0, "title": "AstraZeneca's inhaler for lung disease shows improved function in late stage trail", "locations": [], "entities": {"persons": [{"name": "jason neely", "sentiment": "none"}, {"name": "justin george varghese", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "astrazeneca", "sentiment": "negative"}, {"name": "glaxosmithkline", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 26, 2018 / 8:08 AM / Updated 9 minutes ago AstraZeneca's inhaler for lung disease shows improved function in late stage trial Reuters Staff 1 Min Read \n(Reuters) - AstraZeneca said its inhaler for chronic obstructive pulmonary disease (COPD) showed improved lung function in a late stage trial that could challenge GlaxoSmithKline’s new three-in-one inhaler. \nThe single inhaler, PT010, showed “statistically significant” improvement in eight of nine lung function main goals in patients with moderate to very severe COPD, the company said on Friday. \nAstraZeneca said there were no unexpected safety or tolerability signals for PT010 identified in the trial. \n(This version of the story has been refiled to fix typo in headline) Reporting by Justin George Varghese in Bengaluru; editing by Jason Neely", "external_links": [], "published": "2018-01-26T10:06:00.000+02:00", "crawled": "2018-01-26T10:36:31.040+02:00", "highlightTitle": ""}